You are viewing the site in preview mode

Skip to main content

Advertisement

Table 1 Prevalence of high-risk human papillomavirus antibodies among women from Santiago, Chile, at baseline in 2001 and follow-up in 2006

From: Serological prevalence and persistence of high-risk human papillomavirus infection among women in Santiago, Chile

  Seropositivity
  Baseline (n = 1021) Follow-up (n = 600)
HPV type n % (95% CI) n % (95% CI)
Any HR-HPVa 442 43.3 (40.2-46.4) 301 50.2 (46.1-54.2)
16 189 18.5 (16.2-21.0) 118 19.7 (16.5-22.9)
18 148 14.5 (12.4-16.8) 110 18.3 (15.2-21.4)
31 92 9.0 (7.3-10.9) 59 9.8 (7.4-12.2)
33 46 4.5 (3.3-6.0) 31 5.2 (3.4-6.9)
35 160 15.7 (13.5-18.0) 109 18.2 (15.1-21.3)
45 142 13.9 (11.8-16.2) 92 15.3 (12.5-18.3)
52 70 6.9 (5.4-8.6) 43 7.2 (5.1-9.2)
58 63 6.2 (4.8-7.8) 44 7.3 (5.2-9.4)
Single type 244 23.9 (21.3-26.5) 149 24.8 (21.4-29.3)
Multiple types 198 19.4 (17.0-21.8) 152 25.3 (21.8-28.8)
  1. aPositive for at least one of the following high risk HPV types: 16, 18, 31, 33, 35, 45, 52, and 58.
  2. HR: high-risk, HPV: human papillomavirus, CI: confidence interval.